Strata Critical Medical, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2025

Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2025 and December 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.





	Level	September 30, 2025		December 31, 2024
Assets
Money market fund (1)	1	$	15,592	$	13,751
Contingent consideration asset (2)	3	27,825		—
Indemnity holdback related to sale of business (2)	3	8,575		—
Total assets at fair value		$	51,992	$	13,751

Liabilities
Warrant liabilities - Public Warrants	1	$	1,906	$	3,758
Warrant liabilities - Private Warrants	2	1,040		2,050
Share-based payment liability-classified (3)	3	12,742		—
Equity consideration in escrow and contingent consideration (4)	3	9,214		—
Total liabilities at fair value		$	24,902	$	5,808

(1) As of September 30, 2025 and December 31, 2024, the Company had cash equivalents held in a money market fund. The Company has concluded that due to the highly liquid nature of the fund, the carrying value approximates fair value, which represents a Level 1 input. The balance of cash equivalents held in the money market fund is included in cash and cash equivalents.

(2) Contingent consideration and indemnity holdback related to sale of business, presented under “Other Non-Current Assets”, in the unaudited interim condensed consolidated balance sheets, was established during the period ended September 30, 2025. Refer to Note 3 for additional information.

(3) Share-based payment liability-classified is presented under “Other Non-Current Liabilities”, in the unaudited interim condensed consolidated balance sheets, was established during the period ended September 30, 2025. Refer to Note 3 for additional information.

(4) Equity consideration in escrow and contingent consideration is presented under “Accounts payable and Accrued Expenses” and “Other Non-Current Liabilities” as applicable, in the unaudited interim condensed consolidated balance sheets, was established during the period ended September 30, 2025. Refer to Note 2 for additional information.

Summary of Change in Fair Value of Warrant Liabilities

The following table presents the changes in fair value of the warrant liabilities:


	Public Warrants		Private Placement Warrants		Total Warrant Liability


Fair value as of January 1, 2025	$	3,758	$	2,050	$	5,808

Change in fair value of warrant liabilities	(1,852)		(1,010)		(2,862)
Fair value as of September 30, 2025	$	1,906	$	1,040	$	2,946